Gui Lu

Prof. Gui Lu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in ACS Catalysis
Verified
Journal Article
Closed access
JLJun-Ming Li
Jun-Ming Li
YWYong-Heng Wang
Yong-Heng Wang
YYYang Yu
Yang Yu
RWRui-Bo Wu
Rui-Bo Wu
JWJiang Weng
Jiang Weng
GLGui Lu
Gui Lu

31 March 2020 in Organic Letters
Verified
Journal Article
Closed access
TZTao Zhong
Tao Zhong
MPMeng-Ke Pang
Meng-Ke Pang
ZCZhi-Da Chen
Zhi-Da Chen
BZBin Zhang
Bin Zhang
JWJiang Weng
Jiang Weng
GLGui Lu
Gui Lu

26 December 2016 in Organic Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
WHWei-Jie Huang
Wei-Jie Huang
QCQing Chen
Qing Chen
NLNing Lin
Ning Lin
XLXian-Wen Long
Xian-Wen Long
WPWei-Gao Pan
Wei-Gao Pan
GLGui Lu
Gui Lu
Unprecedented asymmetric exo′-selective [3 + 2] cycloaddition reactions of CF3-containing isatin-derived azomethine ylides with methyleneindolinones have been disclosed. Under bifunctional organocatalysis by cinchona-derived squaramide catalysts, a series of potential biologically important trifluoromethylated 3,3′-pyrrolidinyl-dispirooxindoles were efficiently constructed in a highly stereoselective manner (84%–99% yields, up to >20 : 1 dr and >99% ee). The reaction leads to the formation of four contiguous stereogenic centers, including two adjacent spiro quaternary stereocenters.

7 June 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
TZTao Zhong
Tao Zhong
JYJi-Tao Yi
Ji-Tao Yi
ZCZhi-Da Chen
Zhi-Da Chen
QZQuan-Can Zhuang
Quan-Can Zhuang
YLYong-Zhao Li
Yong-Zhao Li
JWJiang Weng
Jiang Weng
A three-component aminofluorosulfonylation of unactivated alkenes has been developed by merging photocatalytic PCET with radical relay processes, affording various aliphatic sulfonyl fluorides featuring medicinally privileged heterocyclic scaffolds.

1 August 2014 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
FZFei-Meng Zheng
Fei-Meng Zheng
ZLZi-Jie Long
Zi-Jie Long
ZHZhi-Jie Hou
Zhi-Jie Hou
YLYu Luo
Yu Luo
LXLing-Zhi Xu
Ling-Zhi Xu
QLQuentin Liu
Quentin Liu
Chemoresistance is a major cause of cancer treatment failure. Tumor-initiating cells (TIC) have attracted a considerable amount of attention due to their role in chemoresistance and tumor recurrence. Here, we evaluated the small molecule Aurora kinase inhibitor AKI603 as a novel agent against TICs in breast cancer. AKI603 significantly inhibited Aurora-A (AurA) kinase and induced cell-cycle arrest. In addition, the intragastric administration of AKI603 reduced xenograft tumor growth. Interestingly, we found that breast cancer cells that were resistant to epirubicin expressed a high level of activated AurA and also have a high CD24Low/CD44High TIC population. The inhibition of AurA kinase by AKI603 abolished the epirubicin-induced enrichment of TICs. Moreover, AKI603 suppressed the capacity of cells to form mammosphere and also suppressed the expression of self-renewal genes (β-catenin, c-Myc, Sox2, and Oct4). Thus, our work suggests the potential clinical use of the small molecule Aurora kinase inhibitor AKI603 to overcome drug resistance induced by conventional chemotherapeutics in breast cancer. Mol Cancer Ther; 13(8); 1991–2003. ©2014 AACR.

9 March 2022 in Organic Letters
Verified
Journal Article
Closed access
ZCZhi-Da Chen
Zhi-Da Chen
XZXiang Zhou
Xiang Zhou
JYJi-Tao Yi
Ji-Tao Yi
HDHong-Juan Diao
Hong-Juan Diao
QCQi-Long Chen
Qi-Long Chen
JWJiang Weng
Jiang Weng